Products
Online Inquiry
BMS-536924
Cat. No.:
0225LY-1103
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
BMS-536924 is an ATP-competitive inhibitor targeting IGF-1R and IR (IC50: 100 nM and 73 nM, respectively), showing moderate effects on Lck, Fak, and Mek, with negligible activity toward MAPK1/2 or Akt1.
Synonym:
468740-43-4; BMS536924; 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone; Insulin-like growth factor-1 receptor inhibitor; BMS 536924; (S)-4-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one; 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one; (3M)-4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-benzimidazol-2-yl]pyridin-2(1H)-one
CAS No.:
468740-43-4
Compound CID:
135440466
Formula:
C25H26ClN5O3
Formula Weight:
479.96
Specification
Targets&IC50:
IGF-1R: 100 nM; Insulin receptor: 73 nM
Relative Density:
1.44 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BMS-536924 can be used in cancer biology to examine the dual inhibition of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor kinases.
Library Information
Target:
FAK; IGF-1R; MEK; Src
Receptor:
FAK; IGF-1R; Insulin receptor; Lck; MEK
Pathways:
Angiogenesis; Cytoskeletal signaling; Apoptosis; MAPK; Tyrosine kinase/adaptors
Plate Number:
AOCL-15
Plate Location:
b9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
89 mg/mL; 185.43 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
2.385
HBA_Count:
3
HBD_Count:
4
Rotatable Bond:
6
